KTTA Stock Risk & Deep Value Analysis

Pasithea Therapeutics (KTTA) operates in the high-potential mental health and neurological disorder markets, offering a vast Total Addressable Market. The market cap remains at $0.02B, indicating continued investor caution or stabilization after recent capital raises. While the company holds early-stage intellectual property, progress since the last analysis (45 days ago) is unlikely to have significantly de-risked its profile. It remains pre-revenue and faces immense financial and execution risks, with a high burn rate and persistent threat of dilution. Achieving 10x growth to $0.2B within 3-5 years is still a low-probability, high-reward bet, contingent on major clinical milestones and significant capital infusion, without substantial positive updates in the interim. The score reflects a consistent assessment of its highly speculative nature.